Mitigating the Effects of Nonadherence in Clinical Trials

Overview

Journal J Clin Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2015 Dec 5

PMID 26634893

Citations 42

Authors

Thomas M Shiovitz

Earle E Bain

David J McCann

Phil Skolnick

Thomas Laughren

Adam Hanina

Daniel Burch

Affiliations

Soon will be listed here.

Abstract

Accounting for subject nonadherence and eliminating inappropriate subjects in clinical trials are critical elements of a successful study. Nonadherence can increase variance, lower study power, and reduce the magnitude of treatment effects. Inappropriate subjects (including those who do not have the illness under study, fail to report exclusionary conditions, falsely report medication adherence, or participate in concurrent trials) confound safety and efficacy signals. This paper, a product of the International Society for CNS Clinical Trial Methodology (ISCTM) Working Group on Nonadherence in Clinical Trials, explores and models nonadherence in clinical trials and puts forth specific recommendations to identify and mitigate its negative effects. These include statistical analyses of nonadherence data, novel protocol design, and the use of biomarkers, subject registries, and/or medication adherence technologies.

Citing Articles

Exploring how researchers consider nutrition trial design and participant adherence: a theory-based analysis.

Worthington A, Coffey T, Gillies K, Roy R, Braakhuis A Front Nutr. 2025; 11:1457708.

PMID: 39742103 PMC: 11685074. DOI: 10.3389/fnut.2024.1457708.

Predictors of urine toxicology and other biologic specimen missingness in randomized trials of substance use disorders.

Kelley A, Incze M, Baumgartner M, Campbell A, Nunes E, Scharfstein D Drug Alcohol Depend. 2024; 261:111368.

PMID: 38896944 PMC: 11405181. DOI: 10.1016/j.drugalcdep.2024.111368.

Implementing multicomponent, eHealth-based behaviour change support within a dietary intervention trial improves adherence to study-related behaviours in healthy young adults.

Worthington A, Gillies N, Hannaford R, Roy R, Braakhuis A BMC Nutr. 2023; 9(1):134.

PMID: 37990250 PMC: 10664496. DOI: 10.1186/s40795-023-00798-7.

Innovative Technologies in CNS Trials: Promises and Pitfalls for Recruitment, Retention, and Representativeness.

Lutz J, Pratap A, Lenze E, Bestha D, Lipschitz J, Karantzoulis S Innov Clin Neurosci. 2023; 20(7-9):40-46.

PMID: 37817816 PMC: 10561984.

Pilot Randomized, Double-Blind, Placebo-Controlled Crossover Trial Evaluating the Feasibility of an Intranasal Oxytocin in Improving Social Cognition in Individuals Living with Alzheimer's Disease.

Michaelian J, McCade D, Hoyos C, Brodaty H, Harrison F, Henry J J Alzheimers Dis Rep. 2023; 7(1):715-729.

PMID: 37483320 PMC: 10357119. DOI: 10.3233/ADR-230013.

References

Ho P, Bryson C, Rumsfeld J . Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119(23):3028-35. DOI: 10.1161/CIRCULATIONAHA.108.768986. View

Zanini G, Marone C . A new job: research volunteer?. Swiss Med Wkly. 2005; 135(21-22):315-7. DOI: 10.4414/smw.2005.10956. View

Vrijens B, Urquhart J . Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther. 2014; 95(6):617-26. DOI: 10.1038/clpt.2014.59. View

Devine E, Waters M, Putnam M, Surprise C, OMalley K, Richambault C . Concealment and fabrication by experienced research subjects. Clin Trials. 2013; 10(6):935-48. DOI: 10.1177/1740774513492917. View

Vitolins M, Rand C, Rapp S, Ribisl P, Sevick M . Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000; 21(5 Suppl):188S-94S. DOI: 10.1016/s0197-2456(00)00077-5. View

Kobak K, Leuchter A, DeBrota D, Engelhardt N, Williams J, Cook I . Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response. J Clin Psychopharmacol. 2010; 30(2):193-7. DOI: 10.1097/JCP.0b013e3181d20912. View

Resnik D, Koski G . A national registry for healthy volunteers in phase 1 clinical trials. JAMA. 2011; 305(12):1236-7. PMC: 3094908. DOI: 10.1001/jama.2011.354. View

Brody B, Leon A, Kocsis J . Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers?. Am J Psychiatry. 2011; 168(12):1245-7. DOI: 10.1176/appi.ajp.2011.11060864. View

Vander Stichele R . Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol. 1991; 41(1):27-35. DOI: 10.1007/BF00280102. View

10.

Jaillon P . Healthy volunteers data bank: where and how?. Fundam Clin Pharmacol. 1990; 4 Suppl 2:177s-181s. View

11.

Blaschke T, Osterberg L, Vrijens B, Urquhart J . Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2011; 52:275-301. DOI: 10.1146/annurev-pharmtox-011711-113247. View

12.

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

13.

Servick K . Biomedicine. 'Nonadherence': a bitter pill for drug trials. Science. 2014; 346(6207):288-9. DOI: 10.1126/science.346.6207.288. View

14.

Shiovitz T, Wilcox C, Gevorgyan L, Shawkat A . CNS sites cooperate to detect duplicate subjects with a clinical trial subject registry. Innov Clin Neurosci. 2013; 10(2):17-21. PMC: 3615509. View

15.

Pledger G . Compliance in clinical trials: impact on design, analysis and interpretation. Epilepsy Res Suppl. 1988; 1:125-33. View

16.

Czobor P, Skolnick P . The secrets of a successful clinical trial: compliance, compliance, and compliance. Mol Interv. 2011; 11(2):107-10. PMC: 3109858. DOI: 10.1124/mi.11.2.8. View

17.

Anderson A, Li S, Biswas K, McSherry F, Holmes T, Iturriaga E . Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2011; 120(1-3):135-41. PMC: 3227772. DOI: 10.1016/j.drugalcdep.2011.07.007. View

18.

Lee S, Walker J, Jakul L, Sexton K . Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress Anxiety. 2004; 19(1):10-9. DOI: 10.1002/da.10134. View

19.

Farmer K . Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999; 21(6):1074-90; discussion 1073. DOI: 10.1016/S0149-2918(99)80026-5. View

20.

Anderson A, Li S, Markova D, Holmes T, Chiang N, Kahn R . Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2015; 150:170-4. PMC: 4388163. DOI: 10.1016/j.drugalcdep.2015.01.036. View